Owing to prior vasculitis, G-CSF was initially withheld; however, persistent cytopenia led to re-administration of filgrastim (75 μg), beginning in the second cycle (14 months after the initial episode of vasculitis), after obtaining comprehensive informed consent. Here, CSF3 is linked to vasculitis.